SureTrader
Interactive Brokers Advertisement
Home > Boards > US Listed > Biotechs > Amarin Corp. PLC ADS (AMRN)

Judge....The way it works is both EPA and

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
jessellivermore Member Profile
 
Followed By 75
Posts 6,233
Boards Moderated 0
Alias Born 07/17/06
160x600 placeholder
Amended Statement of Changes in Beneficial Ownership (4/a) "Edgar (US Regulatory)" - 12/4/2017 4:48:02 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 12/4/2017 9:04:12 AM
Real World Data Analysis Shows That Persistent Hypertriglyceridemia Despite Statin Therapy is Associated With Cardiovascular ... "GlobeNewswire Inc." - 11/14/2017 4:30:00 PM
Vascepa® (Icosapent Ethyl) Showed Reductions in Potentially Atherogenic Lipid and Inflammatory Markers in Statin Treated Pat... "GlobeNewswire Inc." - 11/13/2017 4:30:00 PM
Real-World Data Analysis Shows That High Triglyceride Levels Are Associated With Increased Cardiovascular Events and Medical ... "GlobeNewswire Inc." - 11/13/2017 6:00:00 AM
Amarin to Present at the Jefferies London Healthcare Conference "GlobeNewswire Inc." - 11/7/2017 6:00:00 AM
Quarterly Report (10-q) "Edgar (US Regulatory)" - 11/1/2017 6:35:17 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 11/1/2017 6:31:37 AM
Amarin Reports Third Quarter 2017 Financial Results and Provides Update on Operations "GlobeNewswire Inc." - 11/1/2017 5:30:00 AM
Amarin to Report Third Quarter 2017 Results and Host Conference Call on November 1, 2017 "GlobeNewswire Inc." - 10/25/2017 6:00:00 AM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 10/6/2017 7:23:03 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 10/3/2017 4:26:27 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 10/3/2017 4:26:02 PM
Amarin and HLS Therapeutics Announce Agreement to Commercialize Vascepa® in Canada "GlobeNewswire Inc." - 9/25/2017 6:00:00 AM
Confidential Treatment Order (ct Order) "Edgar (US Regulatory)" - 9/22/2017 1:08:41 PM
Amarin to Present at Cantor Global Healthcare Conference "GlobeNewswire Inc." - 9/20/2017 4:30:00 PM
Amarin Appoints Mark W. Salyer to New Position of Chief Commercial Officer "GlobeNewswire Inc." - 9/13/2017 6:00:00 AM
Amarin to Present at Rodman & Renshaw’s Global Investment Conference "GlobeNewswire Inc." - 9/6/2017 6:00:00 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 8/30/2017 4:02:36 PM
Amarin's REDUCE-IT Cardiovascular Outcomes Study of Vascepa to Continue as Planned at Recommendation of Independent Data Moni... "GlobeNewswire Inc." - 8/14/2017 6:00:00 AM
Securities Registration: Employee Benefit Plan (s-8) "Edgar (US Regulatory)" - 8/2/2017 5:06:42 PM
Quarterly Report (10-q) "Edgar (US Regulatory)" - 8/2/2017 6:38:43 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 8/2/2017 6:31:46 AM
Amarin Reports Second Quarter 2017 Financial Results and Provides Update on Operations "GlobeNewswire Inc." - 8/2/2017 5:30:00 AM
Amarin to Report Second Quarter 2017 Results and Host Conference Call on August 2, 2017 "GlobeNewswire Inc." - 7/26/2017 4:30:00 PM
jessellivermore   Thursday, 10/05/17 11:59:16 PM
Re: north40000 post# 115615
Post # of 119173 
Judge....

The way it works is both EPA and AA compete for the same cell membrane receptors...The EPA/AA ratio determines the fraction of receptors that are occupied with EPA and the fraction occupied with AA. Actually both EPA and AA are pro inflammatory but AA is much more pro inflammatory than EPA is. Therefore when the EPA/AA ratio is high more of the receptors are occupied by EPA and this reduces the inflammation...

":>) JL


Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist